TY - JOUR
T1 - A tumefactive demyelinating lesion in a person with MS after five years of fingolimod
AU - Jeung, L.
AU - Smits, L. M.G.
AU - Hoogervorst, E. L.J.
AU - van Oosten, B. W.
AU - Frequin, S. T.F.M.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - A 38-year-old man with relapsing remitting multiple sclerosis (RRMS) developed a tumefactive demyelinating lesion (TDL) after being clinically and radiologically stable on fingolimod for the last five years. TDLs in MS tend to occur early on in the disease and are uncommon in longstanding MS. Compared to other immune modifying drugs used in MS, there is a relatively high and still increasing number of reports describing the development of TDL under treatment with fingolimod, suggesting a causal relation.
AB - A 38-year-old man with relapsing remitting multiple sclerosis (RRMS) developed a tumefactive demyelinating lesion (TDL) after being clinically and radiologically stable on fingolimod for the last five years. TDLs in MS tend to occur early on in the disease and are uncommon in longstanding MS. Compared to other immune modifying drugs used in MS, there is a relatively high and still increasing number of reports describing the development of TDL under treatment with fingolimod, suggesting a causal relation.
UR - http://www.scopus.com/inward/record.url?scp=85079129525&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2020.101978
DO - 10.1016/j.msard.2020.101978
M3 - Article
C2 - 32062445
AN - SCOPUS:85079129525
VL - 40
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
SN - 2211-0348
M1 - 101978
ER -